Status:
UNKNOWN
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Lead Sponsor:
The Second Hospital of Nanjing Medical University
Conditions:
Post-ERCP Acute Pancreatitis
Epinephrine
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication with high costs, significant morbidity and even mortality. The major mechanisms of PEP is ...
Eligibility Criteria
Inclusion
- ERCP surgery is required
- Signed inform consent form and agreed to follow-up on time.
Exclusion
- Acute pancreatitis.
- Pregnancy or history of allergy to epinephrine.
- Serious liver, kidney, heart and coagulation disorders
- Unwilling or inability to provide consent
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03756116
Start Date
October 1 2018
End Date
October 1 2020
Last Update
November 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210011